Tag: GlobeNewswire

• SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated

• Phase 2 proof-of-concept study in patients with ADPKD remains on-track to initiate in the fourth quarter of 2026

• SCY-770 is a potential first-in-class oral direct AMPK activator designed to address multiple underlying drivers of cyst growth and disease progression in ADPKD

JERSEY CITY, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company advancing novel therapies for severe rare diseases, today announced completion of a Phase 1 study of SCY-770, a first-in-class, selective and direct AMP-activated protein kinase (AMPK) activator. The study was conducted to evaluate the safety and tolerability, as well as to characterize the pharmacokinetics of SCY-770 to support dose selection for the Phase 2 study in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).

“We continue to make strong progress toward initiating our Phase 2 study of SCY-770 in patients with ADPKD, and the additional pharmacokinetic and safety data generated in this Phase 1 study provide important insights to support dose selection,” said Todd Minga, M.D., SVP of Research and Development at SCYNEXIS. “We are encouraged by the favorable safety and tolerability profile observed across the doses studied, which supports continued clinical development of SCY-770. Patients living with ADPKD face a significant unmet medical need, as treatment options remain limited. We look forward to advancing this novel, highly selective oral direct AMPK activator, which has the potential to offer a differentiated therapeutic approach and provide meaningful clinical benefit for patients with this progressive disease.”

The Phase 1 study enrolled 25 healthy participants across three cohorts. In the initial cohort, participants received a single 500 mg dose of SCY-770 under fed and fasted conditions. Participants in the subsequent cohorts received SCY-770 at either 750 mg once daily or 500 mg twice daily, or placebo, for seven days. SCY-770 was well tolerated across all cohorts and demonstrated a safety profile consistent with prior clinical experience. Pharmacokinetic data from this and prior studies will inform dose selection for the Phase 2 trial in patients with ADPKD, which remains on track to initiate in the fourth quarter of 2026.

The safety and tolerability of SCY-770 has been well-characterized across multiple clinical trials in approximately 300 participants to date. SCY-770 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of ADPKD.

About ADPKD

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a genetic disease caused by mutations of the PKD1 or PKD2 genes which encode polycystin complex 1 (PC1) or polycystin complex 2 (PC2) proteins, critical for normal tubular epithelial cell function. Patients develop fluid-filled cysts in their kidneys that progressively impair kidney function with more than 50% reaching end-stage renal failure by the age of 60 requiring renal replacement therapies (e.g., dialysis or transplant). The U.S. prevalence of ADPKD is estimated to be 140,000 patients, with approximately 6,000 new cases diagnosed each year. ADPKD currently has only one approved therapy, Jynarque (tolvaptan), which achieved approximately $1.5 billion in U.S. sales in 2024 despite limited patient uptake due to safety, tolerability, and monitoring requirements.

About SCY-770

SCY-770 is a novel, highly selective, oral direct activator of adenosine monophosphate-activated protein kinase (AMPK) being developed as a potential disease-modifying therapy for autosomal dominant polycystic kidney disease (ADPKD), a progressive genetic disorder characterized by significant unmet medical need. By activating AMPK, SCY-770 targets multiple pathways implicated in disease progression, including mTOR and cAMP signaling, which are known to drive cyst growth and fluid secretion. In addition, AMPK activation is associated with reduction in inflammation and fibrosis while improving cellular metabolism, offering a differentiated, multi-mechanistic approach to address the underlying drivers of ADPKD. SCY-770 has been evaluated across multiple clinical trials in approximately 300 participants to date. SCY-770 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of ADPKD.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS’s proprietary antifungal platform “fungerps” includes BREXAFEMME® (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development for the treatment and prevention of invasive fungal diseases. For more information, visit www.scynexis.com.

Forward-Looking Statements

Statements contained in this press release regarding expected future events or results are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: the anticipated initiation of the Phase 2 proof-of-concept study of SCY-770 in ADPKD patients in the fourth quarter of 2026; the use of population pharmacokinetic modeling to support Phase 2 dose selection; and the potential for SCY-770 to serve as a disease-modifying therapy for ADPKD. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in regulatory and other costs in developing products, including the risk that SCYNEXIS may not reach alignment with the FDA on the planned Phase 2 study design on the anticipated timeline or at all. These and other risks are described more fully in SCYNEXIS’ filings with the Securities and Exchange Commission, including without limitation, the section titled “Risk Factors” in its most recent Annual Report on Form 10-K, and in other filings made with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

CONTACT:
Investor Relations
John Fraunces
LifeSci Advisors
Tel: 917-355-2395
jfraunces@lifesciadvisors.com

• SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated

• Phase 2 proof-of-concept study in patients with ADPKD remains on-track to initiate in the fourth quarter of 2026

• SCY-770 is a potential first-in-class oral direct AMPK activator designed to address multiple underlying drivers of cyst growth and disease progression in ADPKD

JERSEY CITY, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company advancing novel therapies for severe rare diseases, today announced completion of a Phase 1 study of SCY-770, a first-in-class, selective and direct AMP-activated protein kinase (AMPK) activator. The study was conducted to evaluate the safety and tolerability, as well as to characterize the pharmacokinetics of SCY-770 to support dose selection for the Phase 2 study in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).

“We continue to make strong progress toward initiating our Phase 2 study of SCY-770 in patients with ADPKD, and the additional pharmacokinetic and safety data generated in this Phase 1 study provide important insights to support dose selection,” said Todd Minga, M.D., SVP of Research and Development at SCYNEXIS. “We are encouraged by the favorable safety and tolerability profile observed across the doses studied, which supports continued clinical development of SCY-770. Patients living with ADPKD face a significant unmet medical need, as treatment options remain limited. We look forward to advancing this novel, highly selective oral direct AMPK activator, which has the potential to offer a differentiated therapeutic approach and provide meaningful clinical benefit for patients with this progressive disease.”

The Phase 1 study enrolled 25 healthy participants across three cohorts. In the initial cohort, participants received a single 500 mg dose of SCY-770 under fed and fasted conditions. Participants in the subsequent cohorts received SCY-770 at either 750 mg once daily or 500 mg twice daily, or placebo, for seven days. SCY-770 was well tolerated across all cohorts and demonstrated a safety profile consistent with prior clinical experience. Pharmacokinetic data from this and prior studies will inform dose selection for the Phase 2 trial in patients with ADPKD, which remains on track to initiate in the fourth quarter of 2026.

The safety and tolerability of SCY-770 has been well-characterized across multiple clinical trials in approximately 300 participants to date. SCY-770 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of ADPKD.

About ADPKD

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a genetic disease caused by mutations of the PKD1 or PKD2 genes which encode polycystin complex 1 (PC1) or polycystin complex 2 (PC2) proteins, critical for normal tubular epithelial cell function. Patients develop fluid-filled cysts in their kidneys that progressively impair kidney function with more than 50% reaching end-stage renal failure by the age of 60 requiring renal replacement therapies (e.g., dialysis or transplant). The U.S. prevalence of ADPKD is estimated to be 140,000 patients, with approximately 6,000 new cases diagnosed each year. ADPKD currently has only one approved therapy, Jynarque (tolvaptan), which achieved approximately $1.5 billion in U.S. sales in 2024 despite limited patient uptake due to safety, tolerability, and monitoring requirements.

About SCY-770

SCY-770 is a novel, highly selective, oral direct activator of adenosine monophosphate-activated protein kinase (AMPK) being developed as a potential disease-modifying therapy for autosomal dominant polycystic kidney disease (ADPKD), a progressive genetic disorder characterized by significant unmet medical need. By activating AMPK, SCY-770 targets multiple pathways implicated in disease progression, including mTOR and cAMP signaling, which are known to drive cyst growth and fluid secretion. In addition, AMPK activation is associated with reduction in inflammation and fibrosis while improving cellular metabolism, offering a differentiated, multi-mechanistic approach to address the underlying drivers of ADPKD. SCY-770 has been evaluated across multiple clinical trials in approximately 300 participants to date. SCY-770 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of ADPKD.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS’s proprietary antifungal platform “fungerps” includes BREXAFEMME® (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development for the treatment and prevention of invasive fungal diseases. For more information, visit www.scynexis.com.

Forward-Looking Statements

Statements contained in this press release regarding expected future events or results are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: the anticipated initiation of the Phase 2 proof-of-concept study of SCY-770 in ADPKD patients in the fourth quarter of 2026; the use of population pharmacokinetic modeling to support Phase 2 dose selection; and the potential for SCY-770 to serve as a disease-modifying therapy for ADPKD. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in regulatory and other costs in developing products, including the risk that SCYNEXIS may not reach alignment with the FDA on the planned Phase 2 study design on the anticipated timeline or at all. These and other risks are described more fully in SCYNEXIS’ filings with the Securities and Exchange Commission, including without limitation, the section titled “Risk Factors” in its most recent Annual Report on Form 10-K, and in other filings made with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

CONTACT:
Investor Relations
John Fraunces
LifeSci Advisors
Tel: 917-355-2395
jfraunces@lifesciadvisors.com

Milestone marks the first regional franchise group to complete pilot evaluation and advance to commercial deployment following the multinational restaurant parent company’s global vendor approval

Commercial rollout is supported by an initial commercial product order and an exclusive regional distribution agreement in Eastern Europe

VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) — Beyond Oil Ltd. (TSX: BOIL) (OTCQB: BEOLF) (“Beyond Oil” or the “Company”), a food-tech innovation company dedicated to reducing health risks associated with fried food while improving food quality, lowering operational costs, minimizing waste and enhancing sustainability, today announced that a prominent regional franchise group in Eastern Europe has successfully completed its pilot evaluation and is proceeding with a commercial rollout of Beyond Oil’s product across 60 restaurant locations of a leading global fast-food brand in the region. The commercial rollout follows the Company’s news release dated October 1, 2026 regarding the receipt of global vendor approval from the brand’s multinational restaurant parent company, which operates tens of thousands of locations worldwide.

To support the commercial execution of the rollout and establish a localized supply chain, Beyond Oil has entered into an exclusive regional distribution agreement (the “Agreement”) with an established regional foodservice distributor in Eastern Europe. The initial deployment is supported by a committed commercial product order.

This commercial deployment marks the first regional franchisee rollout following Beyond Oil’s corporate approved vendor status with the multinational restaurant parent company, building on more than two years of commercial sales to brand franchise locations in the Middle East. While global approved vendor status establishes corporate procurement clearance across the parent company’s worldwide network of tens of thousands of locations, this milestone demonstrates the direct conversion of corporate validation into franchise-level adoption, committed container volume, and commercial revenue. The regional distributor will also lead broader commercial expansion across eligible regional foodservice operators throughout the territory.

“This commercial rollout represents a pivotal progression for Beyond Oil: moving from operational validation to global corporate approval, and now directly into franchise-level commercial adoption and product sales,” said Jonathan Or, CEO of Beyond Oil. “Securing corporate approved vendor status with one of the world’s largest restaurant parent companies opened the door to tens of thousands of locations globally. Today, with our first regional franchise partner completing its pilot and advancing to a 60-location rollout backed by an initial full container order and dedicated local distribution, we are demonstrating how that corporate clearance translates into commercial execution on the ground. We look forward to executing this initial deployment with the regional distributor and expanding adoption across the brand’s extensive international franchise network.”

Under the terms of the Agreement, the regional distributor has secured exclusive distribution rights in its designated operating territory in Eastern Europe for an initial six-month term, and will oversee regional logistics, customer onboarding, and ongoing product delivery across the participating franchise restaurants. Subject to the distributor maintaining the commercial rollout across its locations in the region and to meeting the Agreement’s ongoing minimum order requirements, the Agreement may remain in effect for an aggregate term of up to three years and six months.

About Beyond Oil Ltd.

We all love fried food. Let’s make it better. Not by changing what people love. By improving the system behind it. Beyond Oil Ltd. (TSX: BOIL, OTCQB: BEOLF) is a food-tech innovation company on a mission to help foodservice operators improve fried food across every dimension that matters: quality, health, consistency, safety, sustainability and profitability. We achieve these outcomes by improving the system behind every kitchen, the frying performance and oil management that determine what lands on the plate. The Company’s patented technology, cleared by the FDA and Health Canada, integrates into existing kitchen workflows to improve frying performance and oil management, helping operators deliver more consistent food, strengthen operational control and reduce oil waste. Beyond Oil’s solution serves restaurant chains, supermarkets, hotels, catering, institutions and industrial frying operations worldwide, turning frying into a measurable, repeatable and scalable brand standard. The result is a better frying standard, helping every fryer, every shift and every plate live up to the food people love. For more information, please visit: www.beyondoil.co.

Forward-Looking Statements and Information

This news release contains “forward-looking statements” within the meaning of the U.S. Securities Act of 1933, the U.S. Securities Exchange Act of 1934, “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of other relevant securities legislation, including applicable securities laws in Canada, which reflect Beyond Oil Ltd.’s current views with respect to, among other things, its operations and financial performance (collectively, “forward-looking statements”). Forward-looking statements include statements that are predictive in nature, depend upon or refer to future results, events or conditions, and include, but are not limited to, statements which reflect management’s current estimates, beliefs and assumptions. Forward-looking statements are typically identified by words such as “expect”, “anticipate”, “believe”, “foresee”, “could”, “estimate”, “goal”, “intend”, “plan”, “seek”, “strive”, “will”, “may” and “should” and similar expressions. In particular, this news release contains forward-looking statements regarding: the timing, pace, and execution of the commercial rollout across franchise restaurant locations in Eastern Europe; the delivery and fulfillment of the initial commercial product order; the ability of the regional distributor to satisfy commercial commitments and rollout milestones required to maintain commercial exclusivity; the potential extension of the Agreement for up to three years and six months; customer retention, re-order rates, oil life extension, and operational performance in commercial kitchens; the expansion of commercial distribution across additional foodservice operators in the region; and management’s expectations regarding regional franchisee adoption and commercial execution under the multinational restaurant parent company’s global approved products list. Forward-looking statements are subject to specific risks and uncertainties, including that the commercial rollout may not result in expected order volumes or sustained product adoption; potential delays in international shipping, logistics, or customs clearance; the risk that individual restaurant locations may discontinue product use; the risk that minimum purchase requirements may not be met, resulting in the loss of exclusivity or termination of the Agreement; and that discussions with other restaurant chains or franchisees may not lead to commercial agreements or system-wide rollouts. Although Beyond Oil Ltd. believes that such forward-looking statements are based upon reasonable estimates, beliefs and assumptions, certain factors, risks and uncertainties, which are described from time to time in our documents filed with the securities regulators in the USA and Canada, could cause actual results to differ materially from those contemplated or implied by forward-looking statements. Readers are urged to consider these risks carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements, which are based only on information available to us as of the date of this news release. Except as required by law, Beyond Oil Ltd. undertakes no obligation to publicly update or revise any forward-looking statements, whether written or oral, that may be as a result of new information, future events or otherwise.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Company Contact:
Adi Olesker, VP of Investor Relations
Phone: +972-50-694-2517
adio@beyondoil.co

Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
BOIL@arxhq.com

Milestone marks the first regional franchise group to complete pilot evaluation and advance to commercial deployment following the multinational restaurant parent company’s global vendor approval

Commercial rollout is supported by an initial commercial product order and an exclusive regional distribution agreement in Eastern Europe

VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) — Beyond Oil Ltd. (TSX: BOIL) (OTCQB: BEOLF) (“Beyond Oil” or the “Company”), a food-tech innovation company dedicated to reducing health risks associated with fried food while improving food quality, lowering operational costs, minimizing waste and enhancing sustainability, today announced that a prominent regional franchise group in Eastern Europe has successfully completed its pilot evaluation and is proceeding with a commercial rollout of Beyond Oil’s product across 60 restaurant locations of a leading global fast-food brand in the region. The commercial rollout follows the Company’s news release dated October 1, 2026 regarding the receipt of global vendor approval from the brand’s multinational restaurant parent company, which operates tens of thousands of locations worldwide.

To support the commercial execution of the rollout and establish a localized supply chain, Beyond Oil has entered into an exclusive regional distribution agreement (the “Agreement”) with an established regional foodservice distributor in Eastern Europe. The initial deployment is supported by a committed commercial product order.

This commercial deployment marks the first regional franchisee rollout following Beyond Oil’s corporate approved vendor status with the multinational restaurant parent company, building on more than two years of commercial sales to brand franchise locations in the Middle East. While global approved vendor status establishes corporate procurement clearance across the parent company’s worldwide network of tens of thousands of locations, this milestone demonstrates the direct conversion of corporate validation into franchise-level adoption, committed container volume, and commercial revenue. The regional distributor will also lead broader commercial expansion across eligible regional foodservice operators throughout the territory.

“This commercial rollout represents a pivotal progression for Beyond Oil: moving from operational validation to global corporate approval, and now directly into franchise-level commercial adoption and product sales,” said Jonathan Or, CEO of Beyond Oil. “Securing corporate approved vendor status with one of the world’s largest restaurant parent companies opened the door to tens of thousands of locations globally. Today, with our first regional franchise partner completing its pilot and advancing to a 60-location rollout backed by an initial full container order and dedicated local distribution, we are demonstrating how that corporate clearance translates into commercial execution on the ground. We look forward to executing this initial deployment with the regional distributor and expanding adoption across the brand’s extensive international franchise network.”

Under the terms of the Agreement, the regional distributor has secured exclusive distribution rights in its designated operating territory in Eastern Europe for an initial six-month term, and will oversee regional logistics, customer onboarding, and ongoing product delivery across the participating franchise restaurants. Subject to the distributor maintaining the commercial rollout across its locations in the region and to meeting the Agreement’s ongoing minimum order requirements, the Agreement may remain in effect for an aggregate term of up to three years and six months.

About Beyond Oil Ltd.

We all love fried food. Let’s make it better. Not by changing what people love. By improving the system behind it. Beyond Oil Ltd. (TSX: BOIL, OTCQB: BEOLF) is a food-tech innovation company on a mission to help foodservice operators improve fried food across every dimension that matters: quality, health, consistency, safety, sustainability and profitability. We achieve these outcomes by improving the system behind every kitchen, the frying performance and oil management that determine what lands on the plate. The Company’s patented technology, cleared by the FDA and Health Canada, integrates into existing kitchen workflows to improve frying performance and oil management, helping operators deliver more consistent food, strengthen operational control and reduce oil waste. Beyond Oil’s solution serves restaurant chains, supermarkets, hotels, catering, institutions and industrial frying operations worldwide, turning frying into a measurable, repeatable and scalable brand standard. The result is a better frying standard, helping every fryer, every shift and every plate live up to the food people love. For more information, please visit: www.beyondoil.co.

Forward-Looking Statements and Information

This news release contains “forward-looking statements” within the meaning of the U.S. Securities Act of 1933, the U.S. Securities Exchange Act of 1934, “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of other relevant securities legislation, including applicable securities laws in Canada, which reflect Beyond Oil Ltd.’s current views with respect to, among other things, its operations and financial performance (collectively, “forward-looking statements”). Forward-looking statements include statements that are predictive in nature, depend upon or refer to future results, events or conditions, and include, but are not limited to, statements which reflect management’s current estimates, beliefs and assumptions. Forward-looking statements are typically identified by words such as “expect”, “anticipate”, “believe”, “foresee”, “could”, “estimate”, “goal”, “intend”, “plan”, “seek”, “strive”, “will”, “may” and “should” and similar expressions. In particular, this news release contains forward-looking statements regarding: the timing, pace, and execution of the commercial rollout across franchise restaurant locations in Eastern Europe; the delivery and fulfillment of the initial commercial product order; the ability of the regional distributor to satisfy commercial commitments and rollout milestones required to maintain commercial exclusivity; the potential extension of the Agreement for up to three years and six months; customer retention, re-order rates, oil life extension, and operational performance in commercial kitchens; the expansion of commercial distribution across additional foodservice operators in the region; and management’s expectations regarding regional franchisee adoption and commercial execution under the multinational restaurant parent company’s global approved products list. Forward-looking statements are subject to specific risks and uncertainties, including that the commercial rollout may not result in expected order volumes or sustained product adoption; potential delays in international shipping, logistics, or customs clearance; the risk that individual restaurant locations may discontinue product use; the risk that minimum purchase requirements may not be met, resulting in the loss of exclusivity or termination of the Agreement; and that discussions with other restaurant chains or franchisees may not lead to commercial agreements or system-wide rollouts. Although Beyond Oil Ltd. believes that such forward-looking statements are based upon reasonable estimates, beliefs and assumptions, certain factors, risks and uncertainties, which are described from time to time in our documents filed with the securities regulators in the USA and Canada, could cause actual results to differ materially from those contemplated or implied by forward-looking statements. Readers are urged to consider these risks carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements, which are based only on information available to us as of the date of this news release. Except as required by law, Beyond Oil Ltd. undertakes no obligation to publicly update or revise any forward-looking statements, whether written or oral, that may be as a result of new information, future events or otherwise.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Company Contact:
Adi Olesker, VP of Investor Relations
Phone: +972-50-694-2517
adio@beyondoil.co

Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
BOIL@arxhq.com

Milestone marks the first regional franchise group to complete pilot evaluation and advance to commercial deployment following the multinational restaurant parent company’s global vendor approval

Commercial rollout is supported by an initial commercial product order and an exclusive regional distribution agreement in Eastern Europe

VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) — Beyond Oil Ltd. (TSX: BOIL) (OTCQB: BEOLF) (“Beyond Oil” or the “Company”), a food-tech innovation company dedicated to reducing health risks associated with fried food while improving food quality, lowering operational costs, minimizing waste and enhancing sustainability, today announced that a prominent regional franchise group in Eastern Europe has successfully completed its pilot evaluation and is proceeding with a commercial rollout of Beyond Oil’s product across 60 restaurant locations of a leading global fast-food brand in the region. The commercial rollout follows the Company’s news release dated October 1, 2026 regarding the receipt of global vendor approval from the brand’s multinational restaurant parent company, which operates tens of thousands of locations worldwide.

To support the commercial execution of the rollout and establish a localized supply chain, Beyond Oil has entered into an exclusive regional distribution agreement (the “Agreement”) with an established regional foodservice distributor in Eastern Europe. The initial deployment is supported by a committed commercial product order.

This commercial deployment marks the first regional franchisee rollout following Beyond Oil’s corporate approved vendor status with the multinational restaurant parent company, building on more than two years of commercial sales to brand franchise locations in the Middle East. While global approved vendor status establishes corporate procurement clearance across the parent company’s worldwide network of tens of thousands of locations, this milestone demonstrates the direct conversion of corporate validation into franchise-level adoption, committed container volume, and commercial revenue. The regional distributor will also lead broader commercial expansion across eligible regional foodservice operators throughout the territory.

“This commercial rollout represents a pivotal progression for Beyond Oil: moving from operational validation to global corporate approval, and now directly into franchise-level commercial adoption and product sales,” said Jonathan Or, CEO of Beyond Oil. “Securing corporate approved vendor status with one of the world’s largest restaurant parent companies opened the door to tens of thousands of locations globally. Today, with our first regional franchise partner completing its pilot and advancing to a 60-location rollout backed by an initial full container order and dedicated local distribution, we are demonstrating how that corporate clearance translates into commercial execution on the ground. We look forward to executing this initial deployment with the regional distributor and expanding adoption across the brand’s extensive international franchise network.”

Under the terms of the Agreement, the regional distributor has secured exclusive distribution rights in its designated operating territory in Eastern Europe for an initial six-month term, and will oversee regional logistics, customer onboarding, and ongoing product delivery across the participating franchise restaurants. Subject to the distributor maintaining the commercial rollout across its locations in the region and to meeting the Agreement’s ongoing minimum order requirements, the Agreement may remain in effect for an aggregate term of up to three years and six months.

About Beyond Oil Ltd.

We all love fried food. Let’s make it better. Not by changing what people love. By improving the system behind it. Beyond Oil Ltd. (TSX: BOIL, OTCQB: BEOLF) is a food-tech innovation company on a mission to help foodservice operators improve fried food across every dimension that matters: quality, health, consistency, safety, sustainability and profitability. We achieve these outcomes by improving the system behind every kitchen, the frying performance and oil management that determine what lands on the plate. The Company’s patented technology, cleared by the FDA and Health Canada, integrates into existing kitchen workflows to improve frying performance and oil management, helping operators deliver more consistent food, strengthen operational control and reduce oil waste. Beyond Oil’s solution serves restaurant chains, supermarkets, hotels, catering, institutions and industrial frying operations worldwide, turning frying into a measurable, repeatable and scalable brand standard. The result is a better frying standard, helping every fryer, every shift and every plate live up to the food people love. For more information, please visit: www.beyondoil.co.

Forward-Looking Statements and Information

This news release contains “forward-looking statements” within the meaning of the U.S. Securities Act of 1933, the U.S. Securities Exchange Act of 1934, “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of other relevant securities legislation, including applicable securities laws in Canada, which reflect Beyond Oil Ltd.’s current views with respect to, among other things, its operations and financial performance (collectively, “forward-looking statements”). Forward-looking statements include statements that are predictive in nature, depend upon or refer to future results, events or conditions, and include, but are not limited to, statements which reflect management’s current estimates, beliefs and assumptions. Forward-looking statements are typically identified by words such as “expect”, “anticipate”, “believe”, “foresee”, “could”, “estimate”, “goal”, “intend”, “plan”, “seek”, “strive”, “will”, “may” and “should” and similar expressions. In particular, this news release contains forward-looking statements regarding: the timing, pace, and execution of the commercial rollout across franchise restaurant locations in Eastern Europe; the delivery and fulfillment of the initial commercial product order; the ability of the regional distributor to satisfy commercial commitments and rollout milestones required to maintain commercial exclusivity; the potential extension of the Agreement for up to three years and six months; customer retention, re-order rates, oil life extension, and operational performance in commercial kitchens; the expansion of commercial distribution across additional foodservice operators in the region; and management’s expectations regarding regional franchisee adoption and commercial execution under the multinational restaurant parent company’s global approved products list. Forward-looking statements are subject to specific risks and uncertainties, including that the commercial rollout may not result in expected order volumes or sustained product adoption; potential delays in international shipping, logistics, or customs clearance; the risk that individual restaurant locations may discontinue product use; the risk that minimum purchase requirements may not be met, resulting in the loss of exclusivity or termination of the Agreement; and that discussions with other restaurant chains or franchisees may not lead to commercial agreements or system-wide rollouts. Although Beyond Oil Ltd. believes that such forward-looking statements are based upon reasonable estimates, beliefs and assumptions, certain factors, risks and uncertainties, which are described from time to time in our documents filed with the securities regulators in the USA and Canada, could cause actual results to differ materially from those contemplated or implied by forward-looking statements. Readers are urged to consider these risks carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements, which are based only on information available to us as of the date of this news release. Except as required by law, Beyond Oil Ltd. undertakes no obligation to publicly update or revise any forward-looking statements, whether written or oral, that may be as a result of new information, future events or otherwise.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Company Contact:
Adi Olesker, VP of Investor Relations
Phone: +972-50-694-2517
adio@beyondoil.co

Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
BOIL@arxhq.com

New DNA and RNA tests expand CNSide beyond leptomeningeal metastases to molecular profiling across CNS oncology

HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) — CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announced the commercial launch of two new cerebrospinal fluid (CSF)-based molecular profiling tests, available to health care professionals in the United States beginning October 12, 2026:

• CNSide^® CSF Molecular Profile – Solid Tumor (DNA & RNA)
• CNSide^® CSF Molecular Profile – Hematologic Malignancies (DNA & RNA)

CNSide CSF Molecular Profile provides comprehensive DNA and RNA profiling of CNS disease biology from cerebrospinal fluid. The tests analyze more than 300 cancer-related genes in cell-free DNA and more than 1,600 transcripts by RNA sequencing, enabling broad characterization of genomic and transcriptomic alterations, including sequence variants, copy-number alterations, and gene fusions. The Hematologic Malignancies test also supports molecular assessment of clonality.

The launch significantly expands the patient population that can be served by CNSide. While CNSide® CSF Tumor Cell Enumeration (TCE) is focused on patients with suspected or confirmed leptomeningeal metastases, Molecular Profile extends CSF-based molecular testing to primary CNS tumors, solid tumors metastatic to the CNS, and hematologic malignancies involving the CNS.

“Physicians managing cancer in the CNS need more than confirmation that disease is present. They need information they can act on,” said Russell Bradley, President and General Manager of CNSide Diagnostics, LLC. “Molecular Profile adds DNA and RNA findings, including potentially actionable alterations, to the cellular information CNSide already provides, and extends CNSide beyond leptomeningeal metastases to primary CNS tumors and hematologic cancers involving the CNS.”

For patients with leptomeningeal metastases, Molecular Profile can be ordered independently or alongside TCE when both cellular and molecular assessment are clinically appropriate. TCE detects and quantitatively enumerates tumor cells, while Molecular Profile characterizes the DNA and RNA biology of disease, providing complementary cellular and molecular information from the same CSF collection.

The approach underlying CNSide CSF Molecular Profile was recently evaluated in a peer-reviewed, real-world study by Albitar et al., investigators at Genomic Testing Cooperative (GTC), published in The Journal of Liquid Biopsy¹. The study analyzed 1,391 evaluable CSF specimens from patients being evaluated for primary CNS tumors, metastatic CNS disease, and hematologic malignancies involving the CNS. Cancer-related molecular findings were identified in 78.4% of evaluable specimens. The study characterized multiple classes of molecular abnormalities, including sequence variants, copy-number and chromosomal alterations, gene fusions, and clonality. 

CNSide CSF Molecular Profile is offered through CNSide Diagnostics’ collaboration with GTC, announced in July 2026. GTC performs the DNA and RNA sequencing and bioinformatics analysis. CNSide Diagnostics manages test ordering, results delivery, physician support and billing.

The launch builds on CNSide’s established experience in CSF-based oncology diagnostics. Since 2020, more than 11,000 CNSide tests have been performed at more than 120 U.S. cancer institutions. The clinical utility of CNSide CSF tumor-cell analysis in leptomeningeal metastases has been evaluated in 12 peer-reviewed publications, prospective multicenter evidence from the FORESEE clinical study, and real-world clinical experience. 

Ordering Information

Beginning October 12, 2026, health care professionals may order CNSide CSF Molecular Profile tests through CNSide Diagnostics. The tests may be ordered independently or, when appropriate, alongside CNSide CSF Tumor Cell Enumeration. Coverage and reimbursement vary by payer and patient benefit design.

CNSide CSF Tumor Cell Enumeration is a laboratory developed test performed by CNSide Diagnostics, LLC in its CLIA-certified, CAP-accredited laboratory in Houston, Texas. CNSide CSF Molecular Profile tests are laboratory developed tests currently performed for CNSide Diagnostics by Genomic Testing Cooperative, LCA, a CLIA-certified and CAP-accredited reference laboratory. These tests have not been cleared or approved by the U.S. Food and Drug Administration and are available through CNSide Diagnostics to health care professionals in the U.S.

About CNSide Diagnostics, LLC

CNSide Diagnostics, LLC is a wholly owned subsidiary of Cerenome, Inc. that develops and commercializes cerebrospinal fluid-based diagnostic tests for cancers involving the central nervous system. The CNSide^® CSF diagnostics platform combines cellular analysis, biomarker characterization, and molecular profiling to support the detection, characterization, and longitudinal assessment of CNS malignancies.

Current offerings include CNSide^® CSF Tumor Cell Enumeration for patients with suspected or confirmed leptomeningeal metastases and CNSide^® CSF Molecular Profile tests for molecular characterization of primary CNS tumors, solid tumors metastatic to the CNS, and hematologic malignancies involving the CNS. For more information, visit www.cnside-dx.com.

About Cerenome

Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company’s CNSide^® Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing.

Its lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation. By integrating commercial diagnostics, targeted therapeutics, proprietary longitudinal data, and artificial intelligence within a single organization, Cerenome is building a differentiated CNS oncology platform designed to improve patient care while creating long-term shareholder value. For more information, visit https://www.cerenome.com.

Forward-Looking Statements

This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof.

Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.

These statements include, without limitation, statements regarding the timing of availability of CNSide CSF Molecular Profile tests; its expected turnaround time, performance and clinical utility; physician adoption and ordering patterns; the timing and content of additional CNSide menu tests; coverage, billing and reimbursement for CNSide CSF Molecular Profile and other CNSide tests; the Company’s reliance on third-party laboratory service providers; the potential market for CNSide tests; the timing in which CNSide tests are commercially launched and commercialization is expanded; the development and utility of CNSide tests; and expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates.

Actual results may differ materially due to a variety of risks and uncertainties, including those described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, except as required by law.

¹ Albitar M, Charifa A, Agersborg S, et al. Using cell free DNA (cfDNA) and RNA (cfRNA) in the diagnosis and monitoring of primary and metastatic CNS tumors. The Journal of Liquid Biopsy. 2026;14:100500.

Investor Contact
CORE IR
IR@cerenome.com

New DNA and RNA tests expand CNSide beyond leptomeningeal metastases to molecular profiling across CNS oncology

HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) — CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announced the commercial launch of two new cerebrospinal fluid (CSF)-based molecular profiling tests, available to health care professionals in the United States beginning October 12, 2026:

• CNSide^® CSF Molecular Profile – Solid Tumor (DNA & RNA)
• CNSide^® CSF Molecular Profile – Hematologic Malignancies (DNA & RNA)

CNSide CSF Molecular Profile provides comprehensive DNA and RNA profiling of CNS disease biology from cerebrospinal fluid. The tests analyze more than 300 cancer-related genes in cell-free DNA and more than 1,600 transcripts by RNA sequencing, enabling broad characterization of genomic and transcriptomic alterations, including sequence variants, copy-number alterations, and gene fusions. The Hematologic Malignancies test also supports molecular assessment of clonality.

The launch significantly expands the patient population that can be served by CNSide. While CNSide® CSF Tumor Cell Enumeration (TCE) is focused on patients with suspected or confirmed leptomeningeal metastases, Molecular Profile extends CSF-based molecular testing to primary CNS tumors, solid tumors metastatic to the CNS, and hematologic malignancies involving the CNS.

“Physicians managing cancer in the CNS need more than confirmation that disease is present. They need information they can act on,” said Russell Bradley, President and General Manager of CNSide Diagnostics, LLC. “Molecular Profile adds DNA and RNA findings, including potentially actionable alterations, to the cellular information CNSide already provides, and extends CNSide beyond leptomeningeal metastases to primary CNS tumors and hematologic cancers involving the CNS.”

For patients with leptomeningeal metastases, Molecular Profile can be ordered independently or alongside TCE when both cellular and molecular assessment are clinically appropriate. TCE detects and quantitatively enumerates tumor cells, while Molecular Profile characterizes the DNA and RNA biology of disease, providing complementary cellular and molecular information from the same CSF collection.

The approach underlying CNSide CSF Molecular Profile was recently evaluated in a peer-reviewed, real-world study by Albitar et al., investigators at Genomic Testing Cooperative (GTC), published in The Journal of Liquid Biopsy¹. The study analyzed 1,391 evaluable CSF specimens from patients being evaluated for primary CNS tumors, metastatic CNS disease, and hematologic malignancies involving the CNS. Cancer-related molecular findings were identified in 78.4% of evaluable specimens. The study characterized multiple classes of molecular abnormalities, including sequence variants, copy-number and chromosomal alterations, gene fusions, and clonality. 

CNSide CSF Molecular Profile is offered through CNSide Diagnostics’ collaboration with GTC, announced in July 2026. GTC performs the DNA and RNA sequencing and bioinformatics analysis. CNSide Diagnostics manages test ordering, results delivery, physician support and billing.

The launch builds on CNSide’s established experience in CSF-based oncology diagnostics. Since 2020, more than 11,000 CNSide tests have been performed at more than 120 U.S. cancer institutions. The clinical utility of CNSide CSF tumor-cell analysis in leptomeningeal metastases has been evaluated in 12 peer-reviewed publications, prospective multicenter evidence from the FORESEE clinical study, and real-world clinical experience. 

Ordering Information

Beginning October 12, 2026, health care professionals may order CNSide CSF Molecular Profile tests through CNSide Diagnostics. The tests may be ordered independently or, when appropriate, alongside CNSide CSF Tumor Cell Enumeration. Coverage and reimbursement vary by payer and patient benefit design.

CNSide CSF Tumor Cell Enumeration is a laboratory developed test performed by CNSide Diagnostics, LLC in its CLIA-certified, CAP-accredited laboratory in Houston, Texas. CNSide CSF Molecular Profile tests are laboratory developed tests currently performed for CNSide Diagnostics by Genomic Testing Cooperative, LCA, a CLIA-certified and CAP-accredited reference laboratory. These tests have not been cleared or approved by the U.S. Food and Drug Administration and are available through CNSide Diagnostics to health care professionals in the U.S.

About CNSide Diagnostics, LLC

CNSide Diagnostics, LLC is a wholly owned subsidiary of Cerenome, Inc. that develops and commercializes cerebrospinal fluid-based diagnostic tests for cancers involving the central nervous system. The CNSide^® CSF diagnostics platform combines cellular analysis, biomarker characterization, and molecular profiling to support the detection, characterization, and longitudinal assessment of CNS malignancies.

Current offerings include CNSide^® CSF Tumor Cell Enumeration for patients with suspected or confirmed leptomeningeal metastases and CNSide^® CSF Molecular Profile tests for molecular characterization of primary CNS tumors, solid tumors metastatic to the CNS, and hematologic malignancies involving the CNS. For more information, visit www.cnside-dx.com.

About Cerenome

Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company’s CNSide^® Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing.

Its lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation. By integrating commercial diagnostics, targeted therapeutics, proprietary longitudinal data, and artificial intelligence within a single organization, Cerenome is building a differentiated CNS oncology platform designed to improve patient care while creating long-term shareholder value. For more information, visit https://www.cerenome.com.

Forward-Looking Statements

This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof.

Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.

These statements include, without limitation, statements regarding the timing of availability of CNSide CSF Molecular Profile tests; its expected turnaround time, performance and clinical utility; physician adoption and ordering patterns; the timing and content of additional CNSide menu tests; coverage, billing and reimbursement for CNSide CSF Molecular Profile and other CNSide tests; the Company’s reliance on third-party laboratory service providers; the potential market for CNSide tests; the timing in which CNSide tests are commercially launched and commercialization is expanded; the development and utility of CNSide tests; and expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates.

Actual results may differ materially due to a variety of risks and uncertainties, including those described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, except as required by law.

¹ Albitar M, Charifa A, Agersborg S, et al. Using cell free DNA (cfDNA) and RNA (cfRNA) in the diagnosis and monitoring of primary and metastatic CNS tumors. The Journal of Liquid Biopsy. 2026;14:100500.

Investor Contact
CORE IR
IR@cerenome.com

New DNA and RNA tests expand CNSide beyond leptomeningeal metastases to molecular profiling across CNS oncology

HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) — CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announced the commercial launch of two new cerebrospinal fluid (CSF)-based molecular profiling tests, available to health care professionals in the United States beginning October 12, 2026:

• CNSide^® CSF Molecular Profile – Solid Tumor (DNA & RNA)
• CNSide^® CSF Molecular Profile – Hematologic Malignancies (DNA & RNA)

CNSide CSF Molecular Profile provides comprehensive DNA and RNA profiling of CNS disease biology from cerebrospinal fluid. The tests analyze more than 300 cancer-related genes in cell-free DNA and more than 1,600 transcripts by RNA sequencing, enabling broad characterization of genomic and transcriptomic alterations, including sequence variants, copy-number alterations, and gene fusions. The Hematologic Malignancies test also supports molecular assessment of clonality.

The launch significantly expands the patient population that can be served by CNSide. While CNSide® CSF Tumor Cell Enumeration (TCE) is focused on patients with suspected or confirmed leptomeningeal metastases, Molecular Profile extends CSF-based molecular testing to primary CNS tumors, solid tumors metastatic to the CNS, and hematologic malignancies involving the CNS.

“Physicians managing cancer in the CNS need more than confirmation that disease is present. They need information they can act on,” said Russell Bradley, President and General Manager of CNSide Diagnostics, LLC. “Molecular Profile adds DNA and RNA findings, including potentially actionable alterations, to the cellular information CNSide already provides, and extends CNSide beyond leptomeningeal metastases to primary CNS tumors and hematologic cancers involving the CNS.”

For patients with leptomeningeal metastases, Molecular Profile can be ordered independently or alongside TCE when both cellular and molecular assessment are clinically appropriate. TCE detects and quantitatively enumerates tumor cells, while Molecular Profile characterizes the DNA and RNA biology of disease, providing complementary cellular and molecular information from the same CSF collection.

The approach underlying CNSide CSF Molecular Profile was recently evaluated in a peer-reviewed, real-world study by Albitar et al., investigators at Genomic Testing Cooperative (GTC), published in The Journal of Liquid Biopsy¹. The study analyzed 1,391 evaluable CSF specimens from patients being evaluated for primary CNS tumors, metastatic CNS disease, and hematologic malignancies involving the CNS. Cancer-related molecular findings were identified in 78.4% of evaluable specimens. The study characterized multiple classes of molecular abnormalities, including sequence variants, copy-number and chromosomal alterations, gene fusions, and clonality. 

CNSide CSF Molecular Profile is offered through CNSide Diagnostics’ collaboration with GTC, announced in July 2026. GTC performs the DNA and RNA sequencing and bioinformatics analysis. CNSide Diagnostics manages test ordering, results delivery, physician support and billing.

The launch builds on CNSide’s established experience in CSF-based oncology diagnostics. Since 2020, more than 11,000 CNSide tests have been performed at more than 120 U.S. cancer institutions. The clinical utility of CNSide CSF tumor-cell analysis in leptomeningeal metastases has been evaluated in 12 peer-reviewed publications, prospective multicenter evidence from the FORESEE clinical study, and real-world clinical experience. 

Ordering Information

Beginning October 12, 2026, health care professionals may order CNSide CSF Molecular Profile tests through CNSide Diagnostics. The tests may be ordered independently or, when appropriate, alongside CNSide CSF Tumor Cell Enumeration. Coverage and reimbursement vary by payer and patient benefit design.

CNSide CSF Tumor Cell Enumeration is a laboratory developed test performed by CNSide Diagnostics, LLC in its CLIA-certified, CAP-accredited laboratory in Houston, Texas. CNSide CSF Molecular Profile tests are laboratory developed tests currently performed for CNSide Diagnostics by Genomic Testing Cooperative, LCA, a CLIA-certified and CAP-accredited reference laboratory. These tests have not been cleared or approved by the U.S. Food and Drug Administration and are available through CNSide Diagnostics to health care professionals in the U.S.

About CNSide Diagnostics, LLC

CNSide Diagnostics, LLC is a wholly owned subsidiary of Cerenome, Inc. that develops and commercializes cerebrospinal fluid-based diagnostic tests for cancers involving the central nervous system. The CNSide^® CSF diagnostics platform combines cellular analysis, biomarker characterization, and molecular profiling to support the detection, characterization, and longitudinal assessment of CNS malignancies.

Current offerings include CNSide^® CSF Tumor Cell Enumeration for patients with suspected or confirmed leptomeningeal metastases and CNSide^® CSF Molecular Profile tests for molecular characterization of primary CNS tumors, solid tumors metastatic to the CNS, and hematologic malignancies involving the CNS. For more information, visit www.cnside-dx.com.

About Cerenome

Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company’s CNSide^® Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing.

Its lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation. By integrating commercial diagnostics, targeted therapeutics, proprietary longitudinal data, and artificial intelligence within a single organization, Cerenome is building a differentiated CNS oncology platform designed to improve patient care while creating long-term shareholder value. For more information, visit https://www.cerenome.com.

Forward-Looking Statements

This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof.

Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.

These statements include, without limitation, statements regarding the timing of availability of CNSide CSF Molecular Profile tests; its expected turnaround time, performance and clinical utility; physician adoption and ordering patterns; the timing and content of additional CNSide menu tests; coverage, billing and reimbursement for CNSide CSF Molecular Profile and other CNSide tests; the Company’s reliance on third-party laboratory service providers; the potential market for CNSide tests; the timing in which CNSide tests are commercially launched and commercialization is expanded; the development and utility of CNSide tests; and expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates.

Actual results may differ materially due to a variety of risks and uncertainties, including those described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, except as required by law.

¹ Albitar M, Charifa A, Agersborg S, et al. Using cell free DNA (cfDNA) and RNA (cfRNA) in the diagnosis and monitoring of primary and metastatic CNS tumors. The Journal of Liquid Biopsy. 2026;14:100500.

Investor Contact
CORE IR
IR@cerenome.com

OREM, Utah, Oct. 06, 2026 (GLOBE NEWSWIRE) — SunPower Inc. (“SunPower” or the “Company”) (Nasdaq: SPWR), a solar technology, services, and installation company, today announced it broke ground on a solar power system for a new AI data center located in Reno, Nevada.

John Paul Bergh, EVP of Cobalt Power Systems and SunPower New Homes, said, “While not yet at the 100-megawatt-plus scale, this solar project is complex, and its installation is a learning opportunity for us. As such, SunPower is honored to have been awarded the first phase of the Reno AI data center project, reflecting our target of expanding our commercial system capability when rigorous performance specs are required.”

T.J. Rodgers, CEO of SunPower, said, “Our ASP for a residential solar job is about $32 thousand, but our high-tech Silicon Valley installations average $44 thousand with some commercial installations running well over $1 million. Bigger is better on the bottom line.”

About SunPower
SunPower (Nasdaq: SPWR) is a solar technology, services, and installation company focused on delivering reliable and affordable energy solutions. Through its national operating platform and specialized subsidiaries, SunPower serves residential, commercial, new-home, and multifamily customers across the United States. For more information visit www.sunpower.com.

Forward Looking Statements
This press release contains forward-looking statements, including statements concerning the equity for interest exchange and related impacts of the transactions. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “seek,” “plan,” “project,” “target,” “looking ahead,” “look to,” “move into,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements represent SunPower’s current beliefs, estimates and assumptions only as of the date of this press release and information contained in this press release should not be relied upon as representing SunPower’s estimates as of any subsequent date. Forward-looking statements are subject to risks, uncertainties, and assumptions. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Risks include, but are not limited to market risks, trends and conditions. These risks are not exhaustive. For additional information on these risks and uncertainties and other potential factors that could cause actual results to differ from the results predicted, readers should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of our annual report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on April 14, 2026, our quarterly reports on Form 10-Q filed with the SEC, and other documents that we have filed with, or will file with, the SEC. Such filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements in this press release speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SunPower assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Company Contacts:
Sioban Hickie
VP Investor Relations
IR@sunpower.com
(801) 515-8727

Source: SunPower

OREM, Utah, Oct. 06, 2026 (GLOBE NEWSWIRE) — SunPower Inc. (“SunPower” or the “Company”) (Nasdaq: SPWR), a solar technology, services, and installation company, today announced it broke ground on a solar power system for a new AI data center located in Reno, Nevada.

John Paul Bergh, EVP of Cobalt Power Systems and SunPower New Homes, said, “While not yet at the 100-megawatt-plus scale, this solar project is complex, and its installation is a learning opportunity for us. As such, SunPower is honored to have been awarded the first phase of the Reno AI data center project, reflecting our target of expanding our commercial system capability when rigorous performance specs are required.”

T.J. Rodgers, CEO of SunPower, said, “Our ASP for a residential solar job is about $32 thousand, but our high-tech Silicon Valley installations average $44 thousand with some commercial installations running well over $1 million. Bigger is better on the bottom line.”

About SunPower
SunPower (Nasdaq: SPWR) is a solar technology, services, and installation company focused on delivering reliable and affordable energy solutions. Through its national operating platform and specialized subsidiaries, SunPower serves residential, commercial, new-home, and multifamily customers across the United States. For more information visit www.sunpower.com.

Forward Looking Statements
This press release contains forward-looking statements, including statements concerning the equity for interest exchange and related impacts of the transactions. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “seek,” “plan,” “project,” “target,” “looking ahead,” “look to,” “move into,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements represent SunPower’s current beliefs, estimates and assumptions only as of the date of this press release and information contained in this press release should not be relied upon as representing SunPower’s estimates as of any subsequent date. Forward-looking statements are subject to risks, uncertainties, and assumptions. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Risks include, but are not limited to market risks, trends and conditions. These risks are not exhaustive. For additional information on these risks and uncertainties and other potential factors that could cause actual results to differ from the results predicted, readers should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of our annual report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on April 14, 2026, our quarterly reports on Form 10-Q filed with the SEC, and other documents that we have filed with, or will file with, the SEC. Such filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements in this press release speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SunPower assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Company Contacts:
Sioban Hickie
VP Investor Relations
IR@sunpower.com
(801) 515-8727

Source: SunPower